MLH1 and breast cancer: The standardized incidence ratio for breast cancer was also elevated (3.95) in a prospective investigation of a cohort of 446 unaffected carriers of MLH1, MSH2, MSH6, and PMS2 mutation over a median follow-up of five years [11].